Mind Medicine MindMed Inc (MNMD) オプション

Wait until the media starts giving this attention now that this stuff is in phase 3 trials. It will be like the Nasdaq listing but bigger. Going to be one wild ride.

Got a chance, for sure.  200 million in volume could move this exponentially 

Been a long day....

Still 45 minutes left in power hour

Hope the guy that had 50k in Calls for 11.00 gets them. Would suck to miss out on that be to only have this hit 11+ next week

For starters.

Tiger this might hit the 40s in 2 months...

Market Cap is at 758,978,969. We want this to get to 2-4B

lol... I read that first part and thought you were going to say that you were going to sh!t when you say the action but couldn't due to the scope. LOL

Literally just got out of my colonoscopy and I'm happy to see this puppy is cleaned out and ready for a massive run!

Up and up from here boys! Shroom Boom 2.0 incoming!

I'm jacked! I'm jacked to the tits!!!

Like the volume, love the price movement 

Greatness 

We will soon see multi year highs here and through the sector.

I sold my 9 and 10 strikes two days ago, of course but still have a ton of shares 

Yes, it is :)

Well, I'm gonna take a bath and say that we get close to 11 today… Well for someone else's sake, we should hit 11 because there were some odd options played for today. They have a strike price of $11

Agreed.  We can hit $70 intraday and close at$55 so he can be right too!

It's looking good premarket 

Highest Price Target from an analyst is 55.00, which is HC Wainwright. However, I think the next big wave is coming just like back in 2021. Next hype train will push these hard ahead of policy change, more news, approvals, media coverage.

Big money will flow in now.

Very nice.  At $70, I'm looking at $300k gain!  I think we are in for a nice ride here for sure!

That's what I'm talking about!

It's bubbling jack...

I'd get a $250,000 gain at $70

Phase 3, Breakthrough Therapy Designation ... and now RFK, Jr. I smell the perfect storm brewing.

25.00 would be a nice start. 70.00 would be end game. 😁

Zoom out to a 3 year chart... this next pop is going to be nice.

I'm seeing upper $70's, and thats not even a 10X, 
Probably join you at $25 with taking back my principal and leaving the free shares in the market. My average is $5, on 5K shares.

I hope they don't get bought out before that price target. 25.00 is fair.

I'm locked and loaded with my first sell order in at $25

This will no organically grow through the year. Should get interesting.

Very nice!

rfk in

RFK about to get in...

get ready for next big leg up!

Yes, it's currently on a few short funds as with ATAI and COMP.

Buying opportunity for me personally.

Buying opportunity for me personally.

Yes. This is already been discussed. It has the highest short interest of any of the stocks in the space.

They will fry soon enough

It’s hard to say but I’m thinking it’s just a little profit taking. It’s been up almost 50% the last few days and I would the traders would be anxious to take some profit. Time will tell.

Is MNMD being shorted?

Let's see if we get a nice green stripe ahead of RFKs final vote next week. Should be a crazy week.

Potential Acquisition of MindMed by J&J or Similar Pharma Companies:

Given Johnson & Johnson’s (J&J) recent acquisition of Intra-Cellular Therapies (ITCI) and its Phase 2 asset for Generalized Anxiety Disorder (GAD), the possibility of J&J or another major pharmaceutical company acquiring MindMed is a realistic scenario.
Why MindMed is an Attractive Acquisition Target

Psychedelic-Based Innovation – MindMed’s MM-120 (LSD-derived treatment) represents a novel approach to GAD that could complement or even disrupt traditional pharmacological treatments. Major pharma companies, including J&J, have been exploring psychedelic-based treatments, evidenced by their previous work with Spravato (esketamine) for depression.

Regulatory Progress and Phase 3 Trials – MM-120 is already in Phase 3 clinical trials and has received Breakthrough Therapy Designation from the FDA. A successful Phase 3 outcome would make MindMed a highly attractive buyout target, as acquiring a late-stage asset could be more efficient than developing a new one in-house.

Market Differentiation – J&J’s acquisition of ITCI suggests they are seeking broader control over the GAD treatment market. However, ITI-1284 operates through a traditional neuropsychiatric mechanism, whereas MM-120 offers a radically different approach via serotonergic psychedelics. This divergence could make MM-120 a highly valuable asset for any pharma company looking to hedge their neuroscience portfolio with a potentially revolutionary treatment.

Big Pharma’s Need for Pipeline Expansion – Large pharmaceutical companies, including J&J, Pfizer, and Merck, are continuously searching for promising late-stage clinical assets to maintain revenue streams as existing drug patents expire. The psychedelic medicine space is emerging as a major area of interest, especially as more clinical data supports the long-term efficacy and safety of these compounds.

Challenges and Considerations

Regulatory Uncertainty – Despite promising trial results, psychedelic-based therapies still face regulatory hurdles and stigma. J&J or another major pharma company may wait until MM-120 secures full FDA approval before making a move.

Cultural Fit and Integration – MindMed is structured as a high-risk, high-reward biotech firm focusing on psychedelic medicine. A large pharmaceutical company might hesitate to fully integrate this approach into a more traditional CNS pipeline.

Competition from Other Pharma Companies – While J&J could be a strong contender to acquire MindMed, other companies with neuroscience portfolios (e.g., AbbVie, Novartis, or Biogen) could also see MM-120 as an opportunity to expand into the psychedelic treatment space.

Conclusion: Likelihood of Acquisition

A J&J acquisition of MindMed is not out of the question, especially given J&J’s ongoing commitment to CNS treatments and GAD. However, whether J&J makes a move could depend on:

The success of MM-120’s Phase 3 trials
Market receptiveness to psychedelic-based treatments
Competitive interest from other pharmaceutical giants

If MM-120 demonstrates clear clinical efficacy and FDA approval seems likely, MindMed will almost certainly become a prime acquisition target in the next 12–24 months. J&J, given its recent neuroscience expansion, could be a logical suitor, but other pharma companies in the CNS space could also enter the fray, making a competitive bidding scenario plausible.

Sweet 

Squeeze

Shs Outstand 81.59M
Shs Float 27.23M
Short Float 38.31%
Short Ratio 6.61
Short Interest 10.43M

9.5M in Volume. Crushing it.

Still has $3, to go but... yes it's going well above $12 in the next couple of weeks 

MNMD, close to a 52/week high

breaking 9.00 today?